Tirzepatide for PCOS: Evidence, Eligibility, Coverage

Tirzepatide is not FDA approved for polycystic ovary syndrome (PCOS). It is approved for type 2 diabetes and heart risk. Some doctors prescribe it when one of those uses also applies. In SURMOUNT-1, people on Zepbound lost 20.9% of body weight on average, vs 3.1% on placebo.

Brands: Mounjaro and Zepbound
Best result (SURMOUNT-1): 20.9% weight loss

Zepbound key facts

How long it lasts in your body

Its half-life runs 5 to 6 days: after 5.5 d half is gone, and after five half-lives (27.5 d) about 3% is left.

Weight lost in the main trial

SURMOUNT-1 over 72 weeks: 20.9% of body weight, compared with 3.1% on placebo.

Cost over time

Monthly prices in US dollars, both list price and self-pay offers, taken from the maker's price page.

Sources: FDA label (DailyMed), Eli Lilly 1 2, cnbc.com.

Who qualifies?

Tirzepatide: who qualifies
Who sets the rule	Who qualifies
Mounjaro	For people aged 10 and older with type 2 diabetes, it lowers blood sugar alongside diet and exercise.
Mounjaro	For high-risk adults with type 2 diabetes, it lowers the risk of heart attack, stroke, or heart-related death.
Zepbound	It helps adults with obesity, and those who are overweight and have a weight-related condition, lose weight and hold onto that loss for the long term, when used with diet and activity.
Zepbound	Moderate to severe obstructive sleep apnea in adults with obesity is treated by this drug.
Medicare GLP-1 Bridge	BMI 35 or higher, no condition needed
Medicare GLP-1 Bridge	You must have BMI 30 or above, plus heart failure, uncontrolled blood pressure, or CKD 3a+
Medicare GLP-1 Bridge	Prediabetes, a past heart attack or stroke, or PAD must also be present, along with a BMI of 27 or higher
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	first, a program for diet and activity lasting 6 months

Sources: FDA label (DailyMed) 1 2, medicare.gov 1 2, aetna.com.

Trial results for PCOS

Not one of these trials enrolled people with only polycystic ovary syndrome (PCOS). Two adult groups were studied: those with obesity or overweight and no diabetes, and those with obesity but not type 2 diabetes.

Trials of tirzepatide in people with polycystic ovary syndrome (PCOS)
Trial	Medicine	Who took part	Length	People	Main result	Comparison
SURMOUNT-1	Zepbound	Adults with obesity or overweight, without diabetes	72 weeks	2,539	20.9% weight loss	3.1% on placebo
SURMOUNT-5	Zepbound	Adults with obesity, without type 2 diabetes	72 weeks	751	20.2% weight loss	Not listed

Trial sources: SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-5 (PubMed).

What is different for PCOS?

Label points for tirzepatide in polycystic ovary syndrome (PCOS)
What changes	What the label says	Labels
Hypoglycemia When Combined With Insulin Secretagogues or Insulin	Taking it with insulin or a sulfonylurea raises the chance of low blood sugar, and those doses may need lowering.	All of them
Taken with birth control pills	For a while, this medicine can reduce how well birth control pills work. Once you start, and again after every dose increase, choose a method that is not oral, or add a barrier method.	All of them

These details come from the FDA labels: FDA label on DailyMed.

These warnings come from the label: FDA label (DailyMed).

Coverage for PCOS

A GLP-1 used only for weight loss is not covered by Medicare Part D.

Under Medicare GLP-1 Bridge, Zepbound is listed at $50 per month for people who meet its rules.

In places where Medicaid covers weight-loss GLP-1s, prior authorization is the norm.

Sources: humana.com, CMS, KFF.

Alternatives for PCOS

GLP-1 medicines and polycystic ovary syndrome (PCOS)
Medicine	For PCOS	How it is taken	Trial result
Mounjaro	Not a listed use	weekly injection	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Ozempic	Not a listed use	weekly injection	Not listed
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Not a listed use	daily tablet	Not listed
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed